Leap Therapeutics Inc
Company Profile
Business description
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
Contact
47 Thorndike Street
Suite B1-1
CambridgeMA02141
USAT: +1 617 714-0360
E: donsi@leaptx.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
52
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,401.80 | 2.00 | 0.02% |
| CAC 40 | 7,626.84 | 70.08 | -0.91% |
| DAX 40 | 23,115.96 | 133.69 | -0.58% |
| Dow JONES (US) | 41,113.97 | 284.97 | 0.70% |
| FTSE 100 | 8,559.33 | 38.09 | -0.44% |
| HKSE | 22,691.88 | 29.17 | 0.13% |
| NASDAQ | 17,738.16 | 48.50 | 0.27% |
| Nikkei 225 | 36,738.28 | 41.38 | -0.11% |
| NZX 50 Index | 12,536.66 | 39.77 | 0.32% |
| S&P 500 | 5,631.28 | 24.37 | 0.43% |
| S&P/ASX 200 | 8,175.40 | 2.90 | -0.04% |
| SSE Composite Index | 3,342.47 | 0.20 | -0.01% |